2019 China BioMed Innovation and Investment Conference (2019 CBIIC) will be held in Suzhou Industrial Park in September 21-23, aiming to integrate the power of pharmaceutical innovation and investment at home and abroad to build an authorized, comprehensive, professional and international high level platform for industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors.

2019 CBIIC Roadshow Application and Participant Registration System is officially online. Participation registration and roadshow application are available now.

Time: September 21-23, 2019

Venue: Suzhou Jinji Lake International Convention Center (Address: 688 East Suzhou Avenue, Suzhou Industrial Park, Suzhou, Jiangsu Province)

Highlights

3500+Participants

700+Pharmaceutical Companies

500+Investment and Financial Institutions

150+Innovative Projects

20+Excellent parallel sessions

10+Countries and areas coverage

Live broadcast of 2019 CBIIC

Latest clinical trial data

Domestic and foreign KOLs gathered

One-on-One partnering system

English-Chinese simultaneous interpretation

Satellite meetings with diversified topics

Domestic and foreign authoritative media report

Application for Clinical Trial Data Release and Roadshow

I. Innovative Drugs (Orphan Drugs included): New molecular entity; new structure, target; new therapies in accordance with drug administration; modified new drugs with clinical value (prodrugs, drugs with new component, dosage forms, new indication or routes of administration)

II. Class II or Class III Medical Devices and Diagnostic Regent with obvious product superiority and authorized approval for clinical trial.

III. Artificial Intelligence (AI), Innovation R&D Services, WIT-MED + Big Data

Due to the limitation of roadshow projects, please apply as soon as possible.

Participation Registration

I. Visit 2019 CBIIC official websitehttp://cbiic.phirda.com/enfor roadshow application and participation registration.

II. View the Instruction for Registration and Roadshow Application for detailed information.

Early Bird Registration ends by July 20.

Brief Introduction of CBIIC

China BioMed Innovation and Investment Conference (CBIIC) was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. As an annual grand conference to promote the communication between pharmaceutical industry and investment industry, CBIIC aims to integrate the power of pharmaceutical innovation and investment at home and abroad to build an authorized, comprehensive, professional and international high level platform for industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors to learn the trend of innovation, seek high value projects and discuss new investment channels and innovative cooperation strategies to facilitate the timely transformation of unmet clinical needs and promote the pharmaceutical innovation serve the public health.

Established by PhIRDA, and successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX) and Chinese Hospital Association (CHA), CBIIC received extensive participation and recognition from domestic and foreign pharmaceutical industry and investment circle. By the end of 2018, over 6,500 participants attended CBIIC, 25 new drugs had made their global first clinical trial data release, more than 300 innovative projects at home and abroad had presented in the roadshows, representatives from 1,500 pharmaceutical enterprises and 1,000 investment institutions participated in this event.

I.Plenty of Roadshows and Parallel Sessions to Meet Diverse Needs

2019 CBIIC will be held in Suzhou Industry Park in September 21-23, aiming to promote the linkage between social capital and pharmaceutical innovation and improve innovation capability of pharmaceutical industry. 2019 CBIIC remains true to its original aspiration, designing activities around the hot spots of pharmaceutical innovation. Almost 20 excellent roadshows and parallel sessions including the newly set Immuno Oncology Forum and WIT-MED and Big Data Roadshow together with the Opening Ceremony, Clinical Trial Data Release, Rare Diseases and Orphan Drugs Roadshow, Medical Devices Roadshow, Artificial Intelligence (AI) Roadshow and Investors’ Experience Sharing Forum, Analysis on latest drug policies etc will present an excellent event and meet diversified needs of participants.

II.KOLs Discuss Hot Topics on Pharmaceutical Policies and Investment Trend

1. Discussion on how to make Sci-Tech Innovation Board the Next NASDAQ by KOLs from Top Leading 5 Stock Exchanges

The investment in pharmaceutical innovation R&D is huge and innovation enterprises need to stabilize their financing channels to solve the problem of continuous investment. R&D start-up companies that stuck in pre-revenue period for long time have difficulty in financing due to capital detention and unsuccessful share transferring. In 2018, HKEX published New Board for the listing of pre-revenue biotech companies, which brought confidence to domestic pharmaceutical innovation enterprises and investors. Pharmaceutical R&D companies like Ascletis, BeiGene, Hua Medicine and Innovent, successfully listed in HKEX. In 2019, Shanghai Stock Exchange launched Science and Technology Innovation Board (Sci-Tech Innovation Board), providing domestic pharmaceutical innovation companies with a more diversified financing channel. For a better and deeper understanding of pharmaceutical innovation financing channel, 2019 CBIIC will invite KOLs from NASDAQ, New York Stock Exchange, London Stock Exchange, HKEX and Shanghai Stock Exchange to discuss the development and future of global innovation Financing Platform.

2. KOLs from Famous International Investment Banks to Analyze China-U.S. Trade Dispute’s Impact on Global Pharmaceutical Market

3. CEO of FibroGen, the first-in-class Roxadustat was first approved in China, Share the Experience in R&D

December 17, 2018, the National Medical Products Administration (NMPA) first approved Roxadustat, a first-in-class HIF-PHI. Thomas B. Neff, CEO of FibroGen, will share with us his experience on conducting pharmaceutical R&D in China.

III.One-on-One Partnering System Provides Opportunities of Close Communication

To facilitate the effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors, 2019 CBIIC will build a better platform for project presentation and communication. Besides the company booths, One-on-One partnering will be provided, participants could seek potential business partners easily and instantly.

We believe that under the great support of all parties, CBIIC will become an internationally impressive event with the authorized and diversified content covering the latest drug policies, clinical trial data, pharmaceutical innovations and new trend of investment in Asia-Pacific region, making social capital play an irreplaceable key role on the development of pharmaceutical innovation, creating a more scientific and attractive investment environment and contributing to China's economic and social development to meet the clinical needs and advance the pursuit of Healthy China.

Attached: 2019 CBIIC Agenda (Draft)